Tracy McGowan

Johnson & Johnson (United States) — United States

Medicine · Health Sciences

19h-index2.7kcitations57works2.52yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Prostate Cancer Treatment and Research(24), Prostate Cancer Diagnosis and Treatment(9), Chronic Kidney Disease and Diabetes(8), Hormonal and reproductive studies(8), Radiopharmaceutical Chemistry and Applications(8)

Publications57 total

Elevating the Patient Voice: Understanding Treatment Preferences in Patients with Advanced Prostate Cancer
Advances in Therapy·2025Open Access
Prostate Cancer Foundation White Paper on Combination Therapy for Metastatic Hormone-Sensitive Prostate Cancer
JCO Oncology Practice·2025· 3 citedOpen Access
Elevating the patient voice: Understanding treatment preferences in patients with advanced prostate cancer.
JCO Oncology Practice·2024
Apalutamide for High-Risk Localized Prostate Cancer Following Radical Prostatectomy (Apa-RP)
The Journal of Urology·2024· 11 citedOpen Access
Impact of a rash management guide in patients receiving apalutamide for high-risk localized prostate cancer in the Apa-RP study
Prostate Cancer and Prostatic Diseases·2024· 4 citedOpen Access
Apa-RP: Multicenter phase 2 study of apalutamide (Apa) and androgen deprivation therapy (ADT) for the treatment of high-risk localized prostate cancer (HR LPC) following radical prostatectomy (RP)—Results in Black and non-Black patients (pts).
Journal of Clinical Oncology·2024· 1 cited
P2-07 APALUTAMIDE FOR HIGH-RISK LOCALIZED PROSTATE CANCER FOLLOWING RADICAL PROSTATECTOMY IN Apa-RP: A Multicenter, Open-Label, Single-Arm Phase 2 Study
The Journal of Urology·2024
Impact of a rash management guide on incidence and severity of rash with apalutamide: Experience from the Apa-RP study in high-risk localized prostate cancer.
Journal of Clinical Oncology·2024· 1 cited
Maintenance of castration with concomitant relugolix and apalutamide (Apa) in patients with high-risk localized prostate cancer (HR-LPC): 1 year update.
Journal of Clinical Oncology·2023· 2 cited
Coadministration of Apalutamide and Relugolix in Patients with Localized Prostate Cancer at High Risk for Metastases
Targeted Oncology·2022· 12 citedOpen Access
Cardiac safety of trabectedin monotherapy or in combination with pegylated liposomal doxorubicin in patients with sarcomas and ovarian cancer
Cancer Medicine·2021· 11 citedOpen Access
Cardiac safety of trabectedin monotherapy and in combination with pegylated liposomal doxorubicin in patients with sarcomas and ovarian cancer.
Journal of Clinical Oncology·2020
Data on prior pegylated liposomal doxorubicin (PLD) treatment in recurrent ovarian cancer: Post-hoc data analysis from the phase 3 randomized, open-label study comparing trabectedin and PLD versus PLD alone in patients with recurrent ovarian cancer
Data in Brief·2020· 3 citedOpen Access
A phase 3 randomized, open-label, multicenter trial for safety and efficacy of combined trabectedin and pegylated liposomal doxorubicin therapy for recurrent ovarian cancer
Gynecologic Oncology·2020· 43 cited
Safety and efficacy of trabectedin when administered in the inpatient versus outpatient setting: Clinical considerations for outpatient administration of trabectedin
Cancer·2019· 14 citedOpen Access
Results of a Real-world Study of Enzalutamide and Abiraterone Acetate With Prednisone Tolerability (REAAcT)
Clinical Genitourinary Cancer·2019· 46 cited
To the Editor, A multicenter, open-label, early access treatment protocol for ibrutinib in patients with relapsed or refractory mantle cell lymphoma
Journal of Oncology Pharmacy Practice·2019· 1 cited
Abstract LB-212: IMAAGEN study biomarker analysis in patients with long term response to abiraterone acetate with prednisone for non-metastatic castrate resistant prostate cancer
Cancer Research·2018
The IMAAGEN Study: Effect of Abiraterone Acetate and Prednisone on Prostate Specific Antigen and Radiographic Disease Progression in Patients with Nonmetastatic Castration Resistant Prostate Cancer
The Journal of Urology·2018· 62 cited
Real-world study of enzalutamide and abiraterone acetate (with prednisone) tolerability (REAAcT): Results.
Journal of Clinical Oncology·2018· 10 cited
page 1 of 3Next →

Frequent Co-authors

Neal D. Shore(17), Anil Londhe(14), Kumar Sharma(12), Charles J. Ryan(10), Daniel R. Saltzstein(7), Jennifer Phillips(7), Pankaj Aggarwal(7), Yanqing Zhu(6), Willie Underwood(6), Philip W. Kantoff(6), Jason Hafron(6), Amitabha Bhaumik(6), Stephen Dunn(5), Peter De Porre(5), Mary B. Todd(5), E. David Crawford(4), Jennifer L. Phillips(4), Roland E. Knoblauch(4), Waleed S.W. Shalaby(4), Karim Fizazi(4)